American Society of Hirudotherapy

Smart Library

Faceted search across all 5 registries. Filter by registry type, evidence level, or safety domain.

Curated knowledge libraryReference collection

New to hirudotherapy? Start here

This library indexes the full evidence base. For orientation, begin with the core guides:

Conditions

17

Cervical Radiculopathy

Tier C

Investigational use for cervical radiculopathy; no verifiable published trial specific to this indication.

InvestigationalMechanistic

Migraine

Tier C

Investigational use with no verifiable published clinical evidence for migraine; the proposed mechanism (reduction of cervico-cranial venous congestion) is hypothetical.

InvestigationalMechanistic

Tension-Type Headache

Tier C

Investigational use for chronic tension headache; no verifiable published clinical evidence — proposed mechanism via reduction of pericranial muscle tension and venous congestion.

InvestigationalMechanistic

Dry Eye Syndrome

Tier C

Investigational use for dry eye disease; proposed mechanism via reduction of meibomian gland inflammation. No verifiable published clinical evidence.

InvestigationalMechanistic

Raynaud's Syndrome (Primary)

Tier C

Investigational use for primary Raynaud's phenomenon; mechanism via local vasodilation and rheologic improvement. No RCT evidence.

InvestigationalMechanistic

Livedo Reticularis

Tier C

Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.

InvestigationalMechanistic

Insulin Injection Lipohypertrophy

Tier C

Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.

InvestigationalMechanistic

Peyronie's Disease (Stable Phase)

Tier C

Investigational use for stable-phase Peyronie's disease; case-report-level evidence only. Standard treatments (verapamil, collagenase, surgery) remain first-line.

InvestigationalMechanistic

Ménière's Disease (Adjunctive)

Tier C

Investigational adjunctive use for Ménière's disease; very limited evidence. Standard management (diet, betahistine, intratympanic therapy) remains primary.

InvestigationalMechanistic

Peripheral Vertigo (BPPV-Refractory / Vestibular Neuritis Recovery)

Tier C

Investigational adjunct for peripheral vertigo persisting after Epley maneuvers or during prolonged vestibular neuritis recovery; anecdotal.

InvestigationalMechanistic

Tarsal Tunnel Syndrome

Tier C

Investigational use for posterior tibial nerve entrapment at the medial ankle; very limited case-report evidence.

InvestigationalMechanistic

Pubic Symphysis Dysfunction (Non-Pregnancy)

Tier C

Investigational use for non-pregnancy-related pubic symphysis dysfunction including athletic osteitis pubis; anecdotal evidence.

InvestigationalMechanistic

Cluster Headache (Episodic)

Tier C

Highly investigational use for episodic cluster headache between attack cycles; very limited anecdotal data, not for active attacks.

InvestigationalMechanistic

Chronic Tension-Type Headache (≥15 Days/Month)

Tier C

Investigational adjunct for chronic tension-type headache (≥15 days/month) with persistent pericranial muscle tenderness; no verifiable published clinical evidence.

InvestigationalMechanistic

Severe Inflammatory Acne Vulgaris

Tier C

Highly investigational use for severe nodulocystic acne refractory to isotretinoin; very limited anecdotal evidence and significant scarring risk concerns.

InvestigationalMechanistic

Cutaneous Lichen Planus (Localized)

Tier C

Investigational use for localized cutaneous lichen planus refractory to topical corticosteroid; very limited case-report evidence.

InvestigationalMechanistic

Chronic Anal Fissure (>8 Weeks)

Tier C

Investigational adjunct for chronic anal fissure refractory to medical therapy; very limited case-report evidence; surgical sphincterotomy remains gold standard.

InvestigationalMechanistic

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Smart Library — Faceted Search Across All Registries | ASH